Amplifon SpAAMFPF 73 Debt-to-EBITDA is 3.96 as of Mar. 2026, which is 22% above its 10-year median of 3.25. GuruFocus rates AMFPF with a GF Score™ of 73/100 and a GF Value™ of $28.60 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 90 Medical Distribution companies, Amplifon SpA ranks worse than 64.44% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Amplifon SpA's Debt-to-EBITDA or its related term are showing as below:
AMFPF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.92 Med: 3.25 Max: 4.28
Current: 3.72
During the past 13 years, the highest Debt-to-EBITDA Ratio of Amplifon SpA was 4.28. The lowest was 1.92. And the median was 3.25.
AMFPF's Debt-to-EBITDA is ranked worse than 64.44% of 90
companies
in the Medical Distribution industry
Industry Median: 2.45
vs AMFPF: 3.72
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Amplifon SpA Debt-to-EBITDA Related Terms
Amplifon SpA Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Amplifon SpA's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Amplifon SpA's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amplifon SpA Debt-to-EBITDA vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Amplifon SpA's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Amplifon SpA's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Amplifon SpA (AMFPF) has a Debt-to-EBITDA of 3.96 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Amplifon SpA. This is 22% above median its historical median of 3.25. Over the past decade, Amplifon SpA's Debt-to-EBITDA has ranged from 1.92 to 4.28. According to the industry distribution chart, Amplifon SpA ranks #58 out of 90 companies in the Medical Distribution industry, placing it in the top 64.4%.
Is Amplifon SpA's Debt-to-EBITDA too high?
Amplifon SpA's current Debt-to-EBITDA of 3.96 is 22% above median its 10-year median of 3.25. Over the past 10 years, this metric has ranged from a low of 1.92 to a high of 4.28. The Medical Distribution industry median Debt-to-EBITDA is 2.45. Amplifon SpA's value of 3.96 is 61.6% above this industry median. Based on the distribution chart, Amplifon SpA ranks #58 out of 90 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Amplifon SpA has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Amplifon SpA's Debt-to-EBITDA compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Amplifon SpA ranks #58 out of 90 companies for Debt-to-EBITDA. This places Amplifon SpA in the lower half of its industry. The industry median Debt-to-EBITDA is 2.45. Amplifon SpA's value of 3.96 is 61.6% above this benchmark. Historically, Amplifon SpA's own Debt-to-EBITDA has ranged from 1.92 to 4.28 over the past decade. While the company's 10-year median is 3.25 vs. the industry median of 2.45, Amplifon SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Distribution company?
The median Debt-to-EBITDA among Medical Distribution companies is 2.45, based on 90 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amplifon SpA's current Debt-to-EBITDA of 3.96 is 61.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Amplifon SpA. For the Medical Distribution industry, the median Debt-to-EBITDA is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amplifon SpA's current Debt-to-EBITDA is 3.96, which is 22% above median its own 10-year median of 3.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amplifon SpA stock overvalued right now?
Based on GuruFocus' analysis, Amplifon SpA (AMFPF) is currently considered Possible Value Trap. The stock's GF Value™ is $28.60, compared to a current price of $11.21 — trading 60.8% below its estimated fair value. The current Debt-to-EBITDA is 3.96, which is 22% above median its 10-year median of 3.25 and 61.6% above the Medical Distribution industry median of 2.45. Amplifon SpA's overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Amplifon SpA (AMFPF), the current Debt-to-EBITDA is 3.96 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amplifon SpA (AMFPF) Overvalued in 2026?
Based on GuruFocus' analysis, Amplifon SpA stock appears to be undervalued.
The current stock price of $11.21 is trading 60.8% below its estimated GF Value™ of $28.60.
GuruFocus considers Amplifon SpA to be Possible Value Trap.
Key valuation signals for AMFPF:
Debt-to-EBITDA: 3.96 (22% above median its 10-year median of 3.25)
GF Value™: $28.60 vs. price of $11.21 (60.8% below fair value)
Industry Position: 61.6% above the Medical Distribution median (#58 of 90)
No single metric tells the full story. See the AMFPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amplifon SpA provides customizable hearing solutions and services through a distribution network of network affiliates, corporate shops, franchises, and shop-in-shops. The company operates in three segments based on geography: the Americas; Europe, the Middle East, and Africa; and Asia-Pacific. It generates the majority of its revenue in the EMEA region. It operates under a variety of brands in these regions, including Amplifon, Beter Horen, Maxtone, and Miracle-Ear.
73GF Score
Get the complete analysis for AMFPF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMFPF has been successfully added to your 
